This was a hospital based prospective, interventional study which included CKD stage 3-5 patients with higher level of uric acid (male>7mg/dl, female>6mg/dl) 
Introduction
The prevalence of chronic kidney disease (CKD) is rapidly increasing worldwide. In the United States, recent data from the National Health and Nutrition Examination Survey (NHANES) estimate the prevalence of CKD to be 9.6% in non institutionalized adults, corresponding to approximately 19 million people. Population-based studies on the prevalence of kidney damage are limited in developing countries. There are only some few studies in Bangladesh showed an alarmingly high prevalence of CKD particularly CKD associated with insulin resistance in middleincome, urban Bangladeshis (Anand et al. 2014 ).In patients with renal disease, there is decreased uric acid (UA) urinary excretion, and whether this will give rise to hyperuricaemia depends on the gastrointestinal excretory compensation (Goicoechea et al., 2010) . Chronic hyperuricaemia would stimulate the renin-angiotensin system and inhibit release of endothelial nitric oxide, contributing to renal vasoconstriction and increasing BP, at the same time, high levels of uric acid may have a pathogenetic role in interstitial inflammation and progression of renal disease Johnson et al., 2003) . Asymptomatic hyperuricaemia is commonly viewed as an entity that should not be treated (Duffy et al.,1981 ; Kanellis et al., 2004) . Some shortterm trials suggest a benefit from lowering uric acid on BP (Feig DI and endothelial dysfunction (Mercuro G et al., 2004) . However, there is increasing evidence that hyperuricaemia may not be completely benign and it is still unknown whether treatment of asymptomatic hyperuricaemia in low-risk patients would provide benefit to patients in terms of renal function, endothelial dysfunction, and blood pressure (Kanbay M et al., 2011) . A correlation of CRP, a marker of subclinical inflammation related to atherosclerosis, and serum UA levels has been described in a recent study by Ruggiero et al (2006) . In their study they found a significant independent association has been found between uric acid and inflammatory markers, such as a white blood cell count, CRP, interleukins, and TNF levels. There are very few data regarding the effect of allopurinol treatment on the inflammatory markers in CKD stage 3, stage 4 and stage 5 patients. In a recent study by Goicoechea et al.(2010) showed that allopurinol treatment decreases CRP levels, slows the progression of renal disease, decreases the number of hospitalizations and reduces cardiovascular risk.
The current study had been designed to see the effect of allopurinol treatment on inflammatory markers in patients with CKD stage 3-5 with asymptomatic hyperuricaemia.
Rationale
It is clear that treatment of chronic kidney disease and its advanced stage end stage renal disease is expensive and beyond the reach of average Bangladeshis.
The resources and skill for taking care of the large CKD load, both in terms of personal and health care infrastructure do not exist currently in our country and would need to be created To tackle the problem of limited access to renal replacement therapy, an important method would be to try and reduce the incidence of end stage renal disease and the need of renal replacement therapy by preventive measures.
Elevated serum uric acid increase the risk of developing chronic renal dysfunction (Ling Li et al., 2014). As hyperuricaemia is associated with CKD and may often remain asymptomatic , if hyperuricaemic patients could be identified and treated properly even asymptomatic it might be possible to halt the progression of CKD and reduce the extra load of ESRD patients which will be highly economical for a economically constrained country like Bangladesh.
Considering the above-mentioned facts and the fact this study was performed to determine the effect of allopurinol in reduction of hyperuricaemia and inflammatory response and thus slowing the progression of renal function.
Hypothesis
Allopurinol may reduce the inflammatory response in patients with chronic kidney disease stage 3 -5 with asymptomatic hyperuricaemia.
Objectives

General objectives:
To evaluate the effect of allopurinol on inflammatory markers such as CRP and ESR in patients with chronic kidney disease (stage 3-5) with asymptomatic hyperuricaemia. 
Methods of Data Collection:
One hundred and twenty patients were enrolled in this study selected from out patients and in patients of department of Nephrology, Dhaka Medical College Hospital, who fulfilled the inclusion and exclusion criteria set for this study. All the patients were briefed in details about the purpose and nature of the study. The patients of control group were also explained properly regarding the nature of their participation in the study. All the patients of the study gave written consent to be enrolled in the study.
One hundred and twenty patients were distributed in two groups. Sixty patients were placed in treatment group and sixty in control group. Purposive sampling technique was followed. However similar pattern of distribution has been attempted by alternative placement of the subjects in treatment and control group by considering i) stages of CKD ii) confounding factors -hypertension and diabetes and iii) treatment history of hypertension and diabetes with similar groups of drugs. Similarly normotensive and non-diabetic patients were placed alternatively in both groups. The dosage of antihypertensive drugs, lipid-lowering agents, antiproteinuric drugs and antiplatelet drugs were continued and adjusted according to the individual patient's clinical condition. Sixty patients of treatment group were administered a dose of 100 mg/d of allopurinol (Goicoechea et al.,2010) . Every patient went through detailed history taking and physical examination. A questionnaire was used to collect demographic data, clinical presentation and findings.
Follow-Up Assessment
• The time of follow-up were 8 months.
• Systolic BP (SBP), diastolic BP (DBP) were recorded and Haemoglobin (Hb) was measured at baseline, at 4, and 8 months after starting treatment to analyze the clinical parameters.
• HbA1c was measured similarly to see the glycaemic status of the patients.
• To determine the effect of allopurinol on inflammatory markers ESR and CRP were measured at baseline and at 4 and 8 months of treatment.
• Serum uric acid was measured similarly to see the effect of allopurinol on asymptomatic hyperuricaemic patients.
• Clinical and biochemical findings were compared between control group and with that of the treatment group.
Adverse Events
Any adverse events considered to be related to the use of allopurinol were recorded during the follow-up assessment. For serious adverse events, allopurinol therapy was discontinued. 
Ethical Consideration:
Prior to the commencement of this study, the thesis protocol was approved by the ethical committee of DMCH, Dhaka. The aims and objectives of the study along with its procedure, risks and benefits of this study were explained to the respondent in easily understandable local language and then informed written consent were taken from each. It was assured that all information and records would be kept confidential and the procedure would be helpful for the researcher. The participant was given the right to withdraw from the study anytime without any explanation. All participant was assured that any complication arise during the procedure would be managed by the researcher.
Results
This was a hospital based prospective interventional study conducted on 120 patients with chronic kidney disease (CKD) stage 3, stage 4 and stage 5 in the department of Nephrology of Dhaka Medical College and Hospital (DMCH) Dhaka. The results were presented by graphs and tables.
In present study mean age was 49 (±9) years in treatment group and 45 (±11) years in control group. (table i) . Male were predominant in both group. In the study 68(56.67%) were male and 52(43.3%) were female. (Fig 1) Initially 60 patients were included in treatment group and 60 patients were included in control group. After 4 th month follow up 3 patients were dropout in treatment group and 4 patients were dropout in control group. After 8 th month follow up in total 07 patients were dropout in treatment group and 09 patients were drop out in control group. Finally 53 patients were included in treatment group and 51 patients were included in control group. (Fig 2) This study showed common etiology of CKD in treatment group and control group where GN, DM, HTN, ADPKD and others were 29(48.33%) vs 24(40%), 24(40%) vs 23(38.33%), 13(21.67%) vs 12(20%), 01(1.67%) vs 1(1.67%) and 08(13.3%) vs 04(6.67%) respectively. (Table II) . Table I shows that mean age is 49 (±9) years in treatment group and 45 (±11) years in control group. There is no significant difference in age between two groups. shows that by sex male were predominant in both groups. 68 (56.67%) were male and 52 (43.3%) were female.
In this study, in CKD stage 3, 06(10%) patients were in treatment group and 10(16.67%) were in control group; in stage 4, 36(60%) were in treatment group and 33(55%) were in control group; in stage 5, 18(30%) were in treatment group and 17(28.33%) were in control group (Table III) . 
Discussion
This prospective study was conducted at department of Nephrology in DMCH, Dhaka where patients were selected by purposive sampling method in control and treatment group as per inclusion and exclusion criteria. There were no significant difference in baseline characteristics between treatment group and control group (p>0.05). In this study, in CKD stage 3, 06(10%) patients were in treatment group and 10(16.67%) were in control group; in stage 4, 36(60%) were in treatment group and 33(55%) were in control group; in stage 5, 18(30%) were in treatment group and 17(28.33%) were in control group.
In present study, no significant change was found in case of both systolic and diastolic blood pressure in treatment group at 4 th and 8 th month follow up (p>0.05). In case of control group similar results were observed. There was no significant change was observed in between treatment group and control group at the end of the study (p>0.05).
A study reported statistical difference between groups in any of the presented clinical markers at baseline was reported in diastolic blood pressure by Kao et al.(2011) .In this trial, diastolic blood pressure was higher in the control group (p=0.036). However, in Siu et al.(2006) an even larger difference in diastolic blood pressure between treatment groups was reported, but this was not reported to be significant (p=0.25).
In case of Hb and HbA1c, no significant differences were found in treatment group at 4th month and 8 th month follow up (p>0.05) from the baseline. In present study, effect of allopurinol on UA level was tried to determine. In treatment group, significant difference was found in case of serum uric acid between baseline (8.14±1.16) and at 4 th month follow up (7.01±0.76) and between baseline (8.14±1.17) and at 8 th month follow up (6.00±0.85) (p<0.001). Serum uric acid was significantly decreased after 8 th month of treatment.
In control group, significant difference was found in case of serum uric acid between baseline and at 4 th month and also between baseline and at 8 th month of follow up (p<0.001). Serum uric acid was significantly increased after 8 th month of follow up.
Goicoechea et al. demonstrated almost similar result in their study. Similarly, in the J-HEALTH study (Ito et al.2012 ), which included 7629 subjects, a change in the eGFR was (negatively) correlated with a change in the serum uric acid level and associated with less cardiovascular events.
In comparison between two groups at 4 th month of follow up no significant differences were found in case of ESR, Hb and HbA1c. But serum uric acid and CRP were significantly decreased at 4 th month in treatment group compared to control group. Hb was found significantly decreased in control group than treatment group after 8 th month of follow up. No significant differences were found in case of ESR and HbA1c in between two groups at 8 th month of follow up. But serum uric acid and CRP were significantly decreased at 8 th month in treatment group compared to control group.
Goicoechea et al. (2010) study showed after 24 months of allopurinol treatment, serum UA levels were significantly decreased in subjects treated with allopurinol, from 7.8 ± 2.1 mg/dl to 6.0 ±1.2 mg/dl (P =0.000), whereas serum UA levels for subjects in the control group remain unchanged throughout the study period (7.3 ±1.6 mg/dl at baseline and 7.5 ±1.7 mg/dl at 24 months) (P = 0.016 between groups and time period). The change in UA levels at 24 months was +0.3 ±0.27 mg/dl in the control group in comparison to -1.6±0.27 mg/dl in the allopurinol group (P =0.000). A correlation of CRP, a marker of subclinical inflammation related to atherosclerosis, and serum UA levels has been described in the study of Ruggiero et al., 2006 . In their study they also found a significant independent association between UA and inflammatory markers, such as CRP (Khosla et al., 2005) . In this present study result shows that allopurinol decreases uric acid and thus CRP levels at the end of 8 th month after compared with the control group.
Multiple studies have demonstrated that uric acid is a potential causative agent of worsening renal function. Over the course of a large volume of literature review, Christin Giordano et al. (2015) have demonstrated that uric acid does indeed affect endothelial function and can contribute to worsening renal disease. Although there is lack of evidence of treating asymptomatic hyperuricaemia , allopurinol may play a role in reducing uric acid and inflammatory marker like CRP and thus retard the further deterioration of renal function.
Conclusion
Allopurinol may have a role in reduction of inflammatory marker CRP. So, allopurinol may have a protective role on renal function by decreasing serum uric acid level and reduction of inflammatory response in patients with chronic kidney disease stage 3 -5 with asymptomatic hyperuricaemia.
Limitations
• Sample size was small.
• Follow up time was short.
• Important confounders that may cause hyperuricaemia (e.g. chronic lymphatic leukaemia, lymphoma, polycythaemia rubra vera, lead toxicity, congenital abnormality etc.) were not properly excluded with relevant investigations.
• The results of our study may be limited by the concomitant use of statins, antiplatelet, and renin-angiotensin-aldosterone system (RAAS) blocker drugs.
Recommendadtions
Allopurinol may play a protective role on renal function in Chronic kidney disease patients with asymptomatic hyperuricaemia by reduction of inflammatory markers. Further research on this topic with a larger sample collected by random sampling and long time follow up is recommended.
